Zydus Lifesciences concludes USFDA inspection at Ahmedabad facility with nil observations
Advertisement
Ahmedabad: Pharma major, Zydus Lifesciences Ltd., has announced that the group’s manufacturing facility at SEZ-2 located at Pharmez, Ahmedabad, underwent aUnited States Food and Drug Administration (USFDA) inspection from 2 nd July to 7 th July, 2023.
The Pre-Approval Inspection (PAI) closed with nil observations.
Medical Dialogues team had earlier reported thatthe Company had received the Establishment Inspection Report (EIR) from the USFDA for the inspection conducted at its manufacturing facility located at Pharmez, Ahmedabad, from March 20 to 24, 2023.
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.